| 1 |
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Xiaowen Tang, Lin Yang, Zheng Li et al. · PubMed
Open access |
2018 |
412 |
| 2 |
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You et al. · Science China Life Sciences
Open access |
7 Mar 2016 |
153 |
| 3 |
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
Fengtao You, Yinyan Wang, Licui Jiang et al. · PubMed
Open access |
2019 |
130 |
| 4 |
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Mingzhi Zhang et al. · Clinical Cancer Research
Open access |
18 Apr 2022 |
119 |
| 5 |
Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
Sujun Li, Lei Xue, Min Wang et al. · OncoTargets and Therapy
Open access |
Jul 2019 |
58 |
| 6 |
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
Ying Chen, Fengtao You, Licui Jiang et al. · Oncotarget
Open access |
15 Mar 2017 |
54 |
| 7 |
The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration
Xingding Zhang, Jing Yu, Yang Qin et al. · The International Journal of Biochemistry & Cell Biology
Open access |
16 Apr 2012 |
47 |
| 8 |
Effects of Csf1R-Targeted Chimeric Antigen Receptor-Modified Nk92Mi & T Cells on Tumor-Associated Macrophages
Ping Zhang, Songbo Zhao, Chao‐Liang Wu et al. · Immunotherapy
|
Aug 2018 |
42 |
| 9 |
La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease
Huimin Meng, Xue Sun, Yanhui Song et al. · Clinical Immunology
|
16 Apr 2018 |
42 |
| 10 |
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia
Xuanqi Cao, Haiping Dai, Qingya Cui et al. · Experimental Hematology and Oncology
Open access |
29 Sep 2022 |
41 |
| 11 |
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma
Haiping Dai, Wei Cui, Qing-ya Cui et al. · Biomarker Research
Open access |
7 Feb 2022 |
34 |
| 12 |
Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization
Dan Chen, Jianxuan Zou, Yunhui Zong et al. · Immunopharmacology and Immunotoxicology
|
8 Mar 2016 |
31 |
| 13 |
MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Xiaochen Zhai, Fengtao You, Shufen Xiang et al. · PubMed
Open access |
2021 |
27 |
| 14 |
Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models
Tian Wang, Kailu Zhang, Fengtao You et al. · Life Sciences
Open access |
12 Aug 2023 |
22 |
| 15 |
B7-H3–Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Licui Jiang, Fengtao You, Hai Jun Wu et al. · Cancer Research
Open access |
6 Sep 2024 |
20 |
| 16 |
Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia
Tingting Zhang, Tian Wang, Fengtao You et al. · Transplant Immunology
Open access |
17 Jan 2022 |
19 |
| 17 |
Successful Treatment of Relapsed/Refractory Extramedullary Multiple Myeloma With Anti-BCMA CAR-T Cell Therapy Followed by Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report and a Review of the Contemporary Literature
Ying Qian, Zijun Qian, Xiujie Zhao et al. · Frontiers in Medicine
Open access |
7 May 2021 |
17 |
| 18 |
CD7 protein plays a crucial role in T cell infiltration in tumors
Binjie Sheng, Kailu Zhang, Shuaiyu Tian et al. · Heliyon
Open access |
Jun 2023 |
13 |
| 19 |
B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia
Shuangshuang Fan, Tian Wang, Fengtao You et al. · European journal of medical research
Open access |
20 Mar 2023 |
12 |
| 20 |
Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
Dan Chen, Fengtao You, Shufen Xiang et al. · PubMed
Open access |
2021 |
12 |
| 21 |
The research significance of concomitant use of CAR-CD138-NK and CAR-CD19-NK to target multiple myelomas
Songbo Zhao, Zhichao Han, Cheng Ji et al. · European Journal of Inflammation
Open access |
2018 |
10 |
| 22 |
Enhanced efficacy of CD19 / CD22 bispecific CAR‐T cells with EAAAK linker on B‐cell malignancies
Renyuxue Ma, Fengtao You, Shuaiyu Tian et al. · European Journal Of Haematology
Open access |
6 Sep 2023 |
9 |
| 23 |
Vincristine/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia
Qing Deng, Shujing Yue, Fengtao You et al. · Acta Biomaterialia
|
16 May 2025 |
7 |
| 24 |
CD7 Nanobody-Based Immuno-Nanotoxin for Targeted Treatment of T-Cell Acute Lymphoblastic Leukemia
Yangyang Dong, Fengtao You, Yifan Zhang et al. · ACS Applied Nano Materials
|
21 Mar 2024 |
5 |
| 25 |
Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
Jinyan Xiao, Yujie Liu, Yifan Shen et al. · Hematological Oncology
Open access |
14 Apr 2025 |
4 |
| 26 |
Zkscan3 gene is a potential negative regulator of plasma cell differentiation
Zixuan Li, Chunmei Wen, Jialu Li et al. · European Journal of Inflammation
Open access |
2019 |
4 |
| 27 |
Allogeneic B7-H3–Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study
Chang Liu et al. · Clinical Cancer Research
|
4 Mar 2026 |
2 |
| 28 |
CD7-Specific Polymersomal Vincristine Delivery Potentiates Chemotherapy in T-Cell Acute Lymphoblastic Leukemia
Z H Zhai, Yifan Zhang, Shujing Yue et al. · Polymer science & technology.
Open access |
17 May 2025 |
2 |
| 29 |
759P Preconditioning with irradiation enhances efficacy of B7-H3-CAR-T in treating solid tumor models
T. Wang, Fu-Rong You, Yinyin Li et al. · Annals of Oncology
Open access |
Sep 2022 |
2 |
| 30 |
A SINGLE‐ARM, OPEN‐LABEL, PILOT TRIAL OF AUTOLOGOUS CD7‐CAR‐T CELLS FOR CD7 POSITIVE RELAPSED AND REFRACTORY T‐LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
Minglan Zhang et al. · Hematological Oncology
Open access |
Jun 2021 |
2 |
| 31 |
Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma
Cheng Ji, Fengtao You, Tingting Zhang et al. · European Journal of Inflammation
Open access |
2020 |
2 |
| 32 |
Discovery of cmpd D6 (FH-001) as a efficiency enhancement and myelosuppression degradation small-molecule fms-like tyrosine kinase 3 inhibitor for the treatment of FLT3-ITD positive acute myeloid leukemia
Yanan Qi, Xinyi Zhu, Jingjing Han et al. · European Journal of Pharmacology
Open access |
27 Mar 2025 |
1 |
| 33 |
Co-Expression of IL-2 Enhances the Efficacy of FLT3-CAR-γδT Cells in Acute Myeloid Leukemia
Xia Wang, Fengtao You, Yulan Gu et al. · Cancers
Open access |
11 Mar 2026 |
0 |
| 34 |
950P A phase I, open-label study of the novel B7-H3 targeted CAR-Vδ1T in patients with advanced solid tumours
Qi Chen, Liu C, J. Li et al. · Annals of Oncology
Open access |
Sep 2025 |
0 |
| 35 |
Concomitant Use of CD138- and CD19-directed Chimeric Antigen Receptor-modified T Cells Enhances Cytotoxicity Towards Multiple Myeloma
Songbo Zhao, Chao Wu, Jialu Li et al. · Journal of Cancer Treatment and Research
Open access |
2021 |
0 |